Yazdanpanah Yazdan
Service Universitaire Régional des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Faculté de Médecine de Lille, 135, rue du Président Coty-B.P.619, F 59208 Tourcoing.
J Antimicrob Chemother. 2004 Apr;53(4):558-61. doi: 10.1093/jac/dkh142. Epub 2004 Feb 25.
As more effective HIV therapies have become available, resource constraints and cost-effectiveness have increasingly been at the centre of the debate on HIV care. Economic analysis is an important methodological approach to the understanding and establishment of priorities for health interventions designed to combat HIV in both high-income and low-income countries. In this paper, I briefly discuss different types of clinical economic analysis, and then consider the cost, affordability and cost-effectiveness of combination antiretroviral therapy in HIV patients in high-income and low-income countries. In high-income countries, HIV disease has become an expensive treatable chronic disease, with annual expenditures per patient of about US$ 20 000. Cost-effectiveness analyses show that antiretroviral therapeutic regimens offer good value for the resources spent compared to many other accepted health care interventions. In low-income countries, major programmes of combination antiretroviral therapy distribution are being planned and becoming operational as drug prices plummet and resources increase. More refined cost-effectiveness analyses are needed to evaluate available HIV/AIDS prevention, treatment, and care, and to identify the interventions that provide the best value for money.
随着更有效的艾滋病病毒治疗方法问世，资源限制和成本效益日益成为艾滋病病毒护理辩论的核心。经济分析是理解和确定高收入和低收入国家防治艾滋病病毒健康干预措施优先事项的重要方法。在本文中，我简要讨论了不同类型的临床经济分析，然后考虑了高收入和低收入国家艾滋病病毒患者联合抗逆转录病毒疗法的成本、可负担性和成本效益。在高收入国家，艾滋病已成为一种昂贵但可治疗的慢性病，每位患者每年的支出约为2万美元。成本效益分析表明，与许多其他公认的医疗保健干预措施相比，抗逆转录病毒治疗方案在资源投入方面具有良好的价值。在低收入国家，随着药品价格暴跌和资源增加，正在规划并实施大规模联合抗逆转录病毒疗法分发项目。需要更精确的成本效益分析来评估现有的艾滋病病毒/艾滋病预防、治疗和护理措施，并确定性价比最高的干预措施。
